Our focus is expanding affordable access to NARCAN® (naloxone HCl) Nasal Spray - the leading
community use naloxone - and progressing our pipeline of opioid overdose and addiction treatments.


Adapt Pharma and Profector Life Sciences Enter a Development and Investment Collaboration

January 5, 2015

Dublin, Ireland—January 15, 2015—Adapt Pharma Limited (“Adapt Pharma”) and Profector Life Sciences Limited (“Profector”) announced a drug development and investment collaboration that will support the continued development of Profector’s advanced gene and cellular delivery technology platforms.

Profector was established in 2011, following 8 years of research and development, as a spin out from the National University of Ireland (NUI), Maynooth. Profector has a scientific instruments business based on its patented electrospinning and electrospray technologies. Customers include leading academic institutions, pharmaceutical companies, and government agencies. Profector is also using this technology to develop therapeutic applications in specialty areas, such as gene and cellular therapy.

Profector’s research team, 18 of whom hold 12 PhDs, is based in Maynooth, Ireland, and its scientific instruments business is based in Cambridge, Massachusetts.

Seamus Mulligan, Chairman and CEO of Adapt, stated, “Profector is an exciting Irish research‐based business with a high caliber team and innovative technologies. We look forward to focusing on drug development opportunities with Profector.”

Dr Michael Maguire, CEO of Profector, stated, “My team and I are excited about bringing Adapt’s business development and pharmaceutical sector expertise to our suite of capabilities. With Adapt, we will work to refine and commercialize our technology platform with therapeutic applications.”

About Profector Life Sciences

Profector is a life science technology business headquartered in Maynooth, Ireland, with US offices in Cambridge, Massachusetts. Spun out from the National University of Ireland (NUI), Maynooth, in 2011, Profector has novel gene and cell delivery platforms. Profector has leveraged its technology platforms to develop to commercial stage breakthrough products in high-growth markets. Profector collaborates with partners to collectively generate value and will continue to leverage its technology platform for therapeutic applications in gene and cellular delivery. Profector has received support from Enterprise Ireland. For more information, please visit www.profector.com.

Media Contact